List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 36 studies with search of: Ribose
Hide studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Completed Treatment of Chronic Fatigue Syndrome and Fibromyalgia With D-ribose- a Multicenter Study
Conditions: Fibromyalgia;   Chronic Fatigue Syndrome
Intervention: Dietary Supplement: Ribose
2 Suspended The Role of Ribose in Patients Diagnosed With Fibromyalgia
Condition: Fibromyalgia
Interventions: Dietary Supplement: D-ribose;   Other: dextrose
3 Recruiting D-Ribose for Fatigue in Subjects With Fibromyalgia
Condition: Fibromyalgia
Interventions: Dietary Supplement: D-Ribose Powder;   Dietary Supplement: Placebo Powder
4 Completed The Effect of Oral D-Ribose in "Baby Boomers" With Fatigue. A Randomized, Double-Blind Study
Condition: Fatigue
Interventions: Dietary Supplement: D-ribose;   Dietary Supplement: Dextrose
5 Terminated The Effect of Ribose on B-Type Natriuretic Peptide (BNP) Levels in Congestive Heart Failure Patients
Condition: Congestive Heart Failure
Intervention: Drug: CORvalen (D-Ribose)
6 Completed Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity
Condition: 5'-Nucleotidase Syndrome
Interventions: Drug: ribose;   Drug: thymidine;   Drug: uridine
7 Active, not recruiting A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
Conditions: Ovarian Neoplasms;   BRCA1 Protein;   BRCA2 Protein
Intervention: Drug: KU-0059436 (AZD2281)(PARP inhibitor)
8 Active, not recruiting Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Condition: Solid Tumour
Intervention: Drug: E7016 + TMZ
9 Recruiting Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma
Condition: Glioblastoma
Intervention: Drug: bsi-201 plus temozolomide
10 Recruiting A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens
Condition: Advanced Solid Tumors
Interventions: Drug: PF-01367338;   Drug: Carboplatin
11 Active, not recruiting A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
Conditions: Medulloblastoma;   Pontine Glioma;   Ependymoma;   Astrocytoma;   PNET
Interventions: Drug: Temozolomide;   Drug: ABT-888
12 Completed Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours
Condition: Neoplasm Metastasis
Intervention: Drug: AZD2281
13 Recruiting Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
Condition: Colorectal Cancer
Intervention: Drug: Veliparib
14 Completed A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention
Condition: Acute Myocardial Infarction
Intervention: Drug: INO-1001
15 Completed ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
Conditions: Leukemia;   Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Other: pharmacological study;   Procedure: biopsy
16 Recruiting A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
Condition: Colorectal Cancer
Intervention: Drug: Temozolomide and ABT-888
17 Recruiting Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide;   Drug: veliparib;   Genetic: gene expression analysis;   Genetic: protein analysis;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
18 Active, not recruiting Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer
Condition: Breast Cancer, Metastatic
Interventions: Drug: Iniparib (SAR240550 - BSI-201);   Drug: Gemcitabine;   Drug: Carboplatin
19 Recruiting ABT-888 and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cavity Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: topotecan hydrochloride;   Drug: veliparib;   Other: laboratory biomarker analysis;   Other: pharmacological study
20 Active, not recruiting Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
Condition: Gastric Cancer
Interventions: Drug: olaparib;   Drug: paclitaxel;   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-36)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services